Back to People

Andrew Venables has more than 30 years’ experience as a financier, lawyer and gene therapist. His career commenced working with the Australian government export financing arm and progressed into corporate banking as a trader and a corporate finance executive in Australia and England. After completing a law degree, he joined the largest Australian law firm where he made Partner in a record time under 3 years. Recognising his work on complex multibillion-dollar transactions, he was named a leading Australian Finance and Mergers and Acquisitions lawyer.

Pursuing his entrepreneurial bent and deep experience in listings, Andrew served as listing CFO in the oil and gas sector on the Norwegian OTC. Andrew serves as a professional independent director. Presently he is the Chairman of a charity for a large hospital in the middle east and the legal director for an accumulation play in the digital media and marketing space.

Andrew’s journey in biotech commenced when his son was born with cystic fibrosis. Returning to England, he assisted the Gene Therapy consortium to with a funding option for a phase 2b lipid trial for cystic fibrosis. Based on the learnings from that experience he founded Loxegen which is developing a novel nanoparticle gene therapy platform for lung disease. Loxegen has achieved significant and prestigious Australian grant funding, several funding offers and various proposals to merge. Loxegen continues under Andrew’s control.

Andrew has an economics degree from Flinders University of South Australia and a law degree from the University of New England with a first-class honours and a, rarely awarded, University Medal. He is the author of a book about the international syndicated loan market.